Tinavi Medical Technologies Co Ltd

Tianzhihang announced that its orthopedic surgery planning software has recently obtained a Class III medical device registration certificate issued by the National Medical Products Administration, valid until August 3, 2031. The software is used in conjunction with the company's orthopedic surgical navigation and positioning system to formulate preoperative plans for adult spinal surgery, total knee replacement surgery, and total hip replacement surgery.

On the evening of July 29, multiple listed companies on the Shanghai and Shenzhen exchanges released significant positive announcements. Tinavi Medical Technologies plans to acquire a 62% equity stake in Shanghai Minimally Invasive Orthopedic Medical Technology through a share issuance, along with raising supporting funds. Upon completion of the deal, the company will complete its orthopedic implant product portfolio, and its shares will resume trading on July 30. Haoneng Corporation plans to invest 1 billion yuan to build a production base for robot joint reducers in Luzhou, with an annual capacity of 5 million units upon completion. Western Mining disclosed its semi-annual report, with operating revenue reaching 39.443 billion yuan in the first half of 2026, up 25% year-on-year, and net profit attributable to shareholders of the listed company reaching 4.169 billion yuan, up 123% year-on-year. Yitian Intelligent's wholly-owned subsidiary Gansu Yisuan signed a computing power resource service contract worth 1.106 billion yuan, with the tax-inclusive contract amount exceeding 100% of the company's audited main business revenue for the most recent fiscal year. The chairman of GigaDevice proposed a share buyback of 1 billion to 2 billion yuan for cancellation, and also plans to increase his shareholding in the company by no less than 1 billion yuan. Yongding Corporation's holding subsidiary Suzhou Dingxin Optoelectronics Technology has received purchase orders for high-power laser chips totaling approximately 1.133 billion yuan over the past month. In addition, Lead Intelligent's foldable screen chip-level polymer 3D printing equipment has achieved mass delivery and production verification, Midea Group's air conditioning dual bases added 200,000 units in European orders within one month, Hengxing New Materials plans to invest approximately 600 million yuan to launch two fine chemical new material projects, and Tianhe Magnetics plans to establish a holding subsidiary to address service gaps in the southern market.

Tinavi Medical announced plans to acquire a 62% stake in Shanghai Orthopaedics, expected to constitute a major asset restructuring, with trading in its shares to resume tomorrow. Yongding Co.'s controlling subsidiary has received purchase orders for high-power laser chip products worth approximately 1.133 billion yuan over the past month. Xingyun Technology's wholly-owned subsidiary has signed a supplementary agreement for computing power services, increasing the contract value to 3.053 billion yuan, up 201.14% from the original agreement. Jiayun Technology shareholder Ruineng Co. plans to acquire an 18.31% stake through a negotiated transfer, and trading in the shares will resume. Lianchuang Electronics' controlling shareholder is set to change to Shouxian Xinqiao, and trading in the shares will resume. GigaDevice Chairman Zhu Yiming has proposed a buyback of A-shares worth between 1 billion and 2 billion yuan for cancellation, and plans to increase his holdings by no less than 1 billion yuan. Sinosun Technology is planning a change of control, and trading in its shares has been suspended. Zijin Mining's controlling subsidiary has terminated its acquisition of Union Gold and plans to subscribe for a 9.2% stake in the company. Huawen Media has had its delisting risk warning removed but will continue to be subject to other risk warnings, with its stock abbreviation changed to ST Huawen. Hailiang Co.'s controlling shareholder has received a commitment letter for an 860 million yuan shareholding increase loan. Huajin Co. Vice General Manager Yan Zenghui has been placed under investigation and subjected to detention measures. Hengrui Medicine's insulin degludec injection has been approved for marketing for the treatment of type 2 diabetes in adults, making it the first domestically developed long-acting insulin analogue in China.

Tinavi plans to acquire a 62% stake in Shanghai Orthopaedics through a share issuance and raise matching funds, which is expected to constitute a major asset restructuring. The company's shares will resume trading on July 30. Moonshot AI's Kimi has completed its Series F funding round, raising over $3.5 billion, with a post-money valuation of $35 billion. The round closed early after being oversubscribed by more than three times the target amount. The Series G round, originally scheduled to start in August, has already been launched ahead of schedule, with a pre-money valuation rising to $50 billion. The Shanghai Stock Exchange has terminated its review of Taosheng Technology's IPO on the STAR Market. Samsung Electro-Mechanics will raise MLCC product shipment prices by 30% starting August 1, while Taiyo Yuden will increase MLCC prices from September 1. Quanta Computer plans to raise up to $2.19 billion through a global depositary share offering. A magnitude 7.1 earthquake in Kumamoto Prefecture, Japan, has halted production at several semiconductor plants, including those of Sony Semiconductor, Renesas Electronics, and Tokyo Electron. Shenzhen has issued a plan to strengthen the research, development, and application of general and vertical models, on-device models, physical AI models, and high-performance intelligent agents.

Tinavi plans to acquire a 62% equity stake in Shanghai Minimally Invasive Orthopedics Medical Technology Co., Ltd. through a share issuance, along with raising matching funds. The deal is expected to constitute a major asset restructuring. Trading in the company’s shares will resume on July 30. Founded in 2009, Shanghai Minimally Invasive Orthopedics is mainly engaged in the research, development, production, and sales of medical devices such as joint implants. Its flagship product, the medial pivot knee, has been implanted in over one million cases worldwide. Tinavi stated that this transaction will fill gaps in its orthopedic implant product matrix and complete its integrated business layout of robots plus implants. The two parties will create synergies in product lines, channels, research and development, and clinical applications. The transaction will not result in a change of the company’s actual controller. The controlling shareholder and actual controller remains Zhang Songgen. On the last trading day before the suspension, Tinavi closed at 19.09 yuan per share, up 8 percent.

Tinavi is planning to acquire a controlling stake in Shanghai Minimally Invasive Orthopaedics Technology by issuing shares and raising matching funds, in a deal expected to constitute a major asset restructuring. Trading in the company's shares will be suspended from 16 July 2026 for no more than five trading days. Jingce Electronic is planning to buy a 41.17 percent stake in Shanghai Jingce Semiconductor Technology through a combination of share issuance, convertible bonds, and cash. After the transaction, Shanghai Jingce will become a wholly owned subsidiary. Trading in the company's shares and convertible bonds will resume on 16 July. Chaozhuo Aviation Technology has halted trading in its shares from 16 July for no more than two trading days, as its controlling shareholder plans a change in control. In other news, several companies have disclosed their half-year earnings forecasts. Among them, Biwin Storage expects a net profit attributable to the parent company of 7 billion to 7.5 billion yuan for the first half, representing a year-on-year increase of 3,200.15 percent to 3,421.59 percent, mainly driven by the explosion in AI computing power and a strong cycle in the storage industry.

MicroPort Scientific has issued a voluntary announcement stating that its subsidiary, Suzhou MicroPort Orthopedics Group, signed a letter of intent on July 15, 2026, with Beijing Tinavi Medical Technologies, proposing to sell its 82.29% equity interest in Shanghai MicroPort Orthopedics Medical Technology. The transaction consideration will be paid through the issuance of new shares by Tinavi. This potential deal is still at a preliminary negotiation stage. Key terms such as the exact transfer ratio, number of shares to be issued, and issue price are subject to further commercial negotiations, and the transaction is conditional upon completion of due diligence, signing of formal agreements, and obtaining relevant regulatory approvals. Shanghai MicroPort Orthopedics serves as the core operating entity for MicroPort Scientific's international orthopedics business, focusing on the research and development of hip and knee joint prostheses and overseas sales. Its medial pivot knee prosthesis has a 17-year implant survival rate of 98.80%, covering markets including the United States, Japan, and Europe. The transaction aims to integrate high-end prosthesis products with intelligent surgical platform resources through strategic synergy with Tinavi, a leading domestic orthopedic surgical robot company, thereby enhancing long-term investment value. The announcement cautions that the potential transaction involves uncertainties and does not constitute a commitment that the deal will necessarily be implemented.